Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses.

ABSTRACT: Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β₂-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled therapy for COPD, based on distinct patient clinical profiles, are unclear. FULFIL, a phase III, randomised, double-blind study, compared 24 weeks of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg using the Ellipta inhaler with twice-daily budesonide/formoterol (BUD/FOR) 400/12 µg using the Turbuhaler. Subgroup analyses of forced expiratory volume in 1 s (FEV₁), St George's Respiratory Questionnaire (SGRQ) Total score and exacerbation r

SUBMITTER: Halpin DMG 

PROVIDER: S-EPMC5934530 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature